Literature DB >> 1967209

Systemic effects of medications used to treat glaucoma.

D E Everitt1, J Avorn.   

Abstract

Medications used to treat glaucoma can have clinically important systemic effects in some patients; these effects may not be recognized in elderly patients who have chronic medical problems and who are taking several systemic medications. Beta-blocking ophthalmic agents are generally safe, but can be absorbed systemically to induce bronchospasm, worsen heart block, decompensate congestive heart failure, or create central nervous system effects in some patients. Reports of adverse systemic effects from miotics, such as pilocarpine, are rare, although cardiovascular decompensation has been seen in patients with acute angle closure who were given excessive doses before surgery. Topical sympathomimetic agents such as epinephrine may increase ventricular extrasystoles and have, on occasion, caused severe hypertensive reactions. Nearly 50% of patients taking carbonic anhydrase inhibitors must discontinue their use because of various adverse constitutional and central nervous system symptoms. Although these drugs are not usually part of internal medicine regimens, they can produce adverse effects that mimic primary disease in nonocular organ systems.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967209     DOI: 10.7326/0003-4819-112-2-120

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  25 in total

1.  Monozygotic twins concordant for both open-angle glaucoma and bronchospasm induced by beta-blockers.

Authors:  P J Gray
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

2.  Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma.

Authors:  Hannu Uusitalo; Mika Kähönen; Auli Ropo; Jukka Mäenpää; Gunilla Bjärnhall; Hans Hedenström; Väinö Turjanmaa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-21       Impact factor: 3.117

3.  Syncope and falls due to timolol eye drops.

Authors:  Marije E Müller; Nathalie van der Velde; Jaap W M Krulder; Tischa J M van der Cammen
Journal:  BMJ       Date:  2006-04-22

4.  Cytotoxicity of pilocarpine to human corneal stromal cells and its underlying cytotoxic mechanisms.

Authors:  Xiao-Long Yuan; Qian Wen; Meng-Yu Zhang; Ting-Jun Fan
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

5.  Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysis.

Authors:  Manuele Michelessi; Kristina Lindsley; Tsung Yu; Tianjing Li
Journal:  Cochrane Database Syst Rev       Date:  2014-11

Review 6.  Beta-adrenergic function in aging. Basic mechanisms and clinical implications.

Authors:  P J Scarpace; N Tumer; S L Mader
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

7.  Treatment for glaucoma: adherence by the elderly.

Authors:  J H Gurwitz; R J Glynn; M Monane; D E Everitt; D Gilden; N Smith; J Avorn
Journal:  Am J Public Health       Date:  1993-05       Impact factor: 9.308

8.  Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension.

Authors:  Anna Galanopoulos; Ivan Goldberg
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 9.  Systemic and local tolerability of ophthalmic drug formulations. An update.

Authors:  F C Hugues; C Le Jeunne
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

10.  Evaluation of risk of falls and orthostatic hypotension in older, long-term topical beta-blocker users.

Authors:  Wishal D Ramdas; Nathalie van der Velde; Tischa J M van der Cammen; Roger C W Wolfs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-19       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.